DEXCOM INC
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures adjusted for later stock splits (split ratios inferred from EPS restated in later SEC filings).
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | – | – |
| Stockholders' equity | 2,746 | 100.0 |
| Total capitalization | 2,746 | 100.0 |
377,360,765 shares outstanding at 23 July 2026 (cover page of the 10-Q filed 30 July 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Not tagged in XBRL |
CAPITAL STOCK 12/31/25
| Common shares authorized | 800,000,000 |
| Common shares issued | 410,700,000 |
| Treasury shares | 25,900,000 |
| Par or stated value per share ($) | 0.001 |
| Outstanding at 7/23/26 | 377,360,765 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 3841, Surgical & Medical Instruments & Apparatus. Large accelerated filer. Principal executive office: 6340 Sequence Drive, San Diego, CA 92121. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 4,662 | 4,033 | 3,622 |
| Cost of revenues | 1,860 | 1,595 | 1,333 |
| Gross profit | 2,802 | 2,438 | 2,289 |
| Research and development | 599 | 552 | 506 |
| Selling, general and administrative | 1,291 | 1,286 | 1,185 |
| Depreciation and amortization | 252 | 218 | 186 |
| Operating income | 912 | 600 | 598 |
| Interest expense | 18 | 19 | 20 |
| Income before income taxes | 1,088 | 709 | 710 |
| Income taxes | 252 | 133 | 169 |
| Net income | 836 | 576 | 542 |
| Earned per share, diluted ($) | 2.09 | 1.42 | 1.30 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 918 | 606 |
| Receivables, net | 1,216 | 1,006 |
| Inventories | 629 | 543 |
| Total current assets | 4,033 | 4,301 |
| Property, plant and equipment, net | 1,560 | 1,340 |
| Goodwill | 24 | 23 |
| Total assets | 6,340 | 6,484 |
| Total current liabilities | 2,142 | 2,932 |
| Total liabilities | 3,594 | 4,382 |
| Stockholders' equity | 2,746 | 2,103 |
| Total liabilities and equity | 6,340 | 6,484 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 4,662 | 912 | 836 | 17.9 | 2.09 | – | 1,441 | 364 | 1,077 | 6,340 | 3,594 | – | 2,746 | 30.5 | – |
| 12/31/24 | 4,033 | 600 | 576 | 14.3 | 1.42 | – | 990 | 359 | 631 | 6,484 | 4,382 | – | 2,103 | 27.4 | – |
| 12/31/23 | 3,622 | 598 | 542 | 14.9 | 1.30 | – | 748 | 237 | 512 | 6,264 | 4,196 | – | 2,069 | 26.2 | – |
| 12/31/22 | 2,910 | 391 | 341 | 11.7 | 0.82 | – | 670 | 365 | 305 | 5,392 | 3,260 | – | 2,132 | 16.0 | – |
| 12/31/21 | 2,448 | 266 | 217 | 8.9 | 0.53 | – | 442 | 389 | 53 | 4,933 | 2,891 | – | 2,042 | 10.6 | – |
| 12/31/20 | 1,927 | 300 | 550 | 28.5 | 1.33 | – | 476 | 199 | 277 | 4,290 | 2,464 | – | 1,552 | 35.4 | – |
| 12/31/19 | 1,476 | 142 | 101 | 6.8 | 0.37 | – | 314 | 180 | 134 | 2,395 | 1,512 | – | 883 | 11.5 | – |
| 12/31/18 | 1,032 | (186) | (127) | -12.3 | (0.48) | – | 123 | 67 | 56 | 1,916 | 1,253 | – | 663 | -19.2 | – |
| 12/31/17 | 718 | (42) | (50) | -7.0 | (0.19) | – | 92 | 66 | 26 | 904 | 485 | – | 419 | -12.0 | – |
| 12/31/16 | 573 | (64) | (66) | -11.4 | (0.26) | – | 56 | 56 | 0 | 403 | 119 | – | 284 | -23.1 | – |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
DEXCOM INC
CIK 1093557 · EIN 33-0857544
PRINCIPAL OFFICE:
6340 Sequence Drive, San Diego, CA 92121
Tel.: 8582000200
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
3841 · Surgical & Medical Instruments & Apparatus
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 12 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/12/26) · 10-K FY2024 (filed 2/18/25) · 10-K FY2023 (filed 2/8/24) · 10-K FY2022 (filed 2/9/23) · 10-K FY2021 (filed 2/14/22) · 10-K FY2020 (filed 2/11/21) · 10-K FY2019 (filed 2/13/20) · 10-K FY2018 (filed 2/21/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.